147 related articles for article (PubMed ID: 33930201)
1. Combination of human papillomaviruses L1 and L2 multiepitope constructs protects mice against tumor cells.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Fundam Clin Pharmacol; 2021 Dec; 35(6):1055-1068. PubMed ID: 33930201
[TBL] [Abstract][Full Text] [Related]
2. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
Namvar A; Bolhassani A; Javadi G; Noormohammadi Z
Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650
[TBL] [Abstract][Full Text] [Related]
3. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
5. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Mol Biotechnol; 2021 Dec; 63(12):1192-1222. PubMed ID: 34308516
[TBL] [Abstract][Full Text] [Related]
6. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
Yadav R; Zhai L; Tumban E
Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
[TBL] [Abstract][Full Text] [Related]
7. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
8. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
9. Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches.
Bagheri A; Nezafat N; Eslami M; Ghasemi Y; Negahdaripour M
Infect Genet Evol; 2021 Nov; 95():105084. PubMed ID: 34547435
[TBL] [Abstract][Full Text] [Related]
10. Dissection of Capsid Protein HPV 52 to Rationalize Vaccine Designs Using Computational Approaches Immunoinformatics and Molecular Docking.
Firdaus MER; Mustopa AZ; Triratna L; Syahputra G; Nurfatwa M
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2243-2253. PubMed ID: 35901328
[TBL] [Abstract][Full Text] [Related]
11. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
Front Immunol; 2020; 11():606569. PubMed ID: 33343580
[TBL] [Abstract][Full Text] [Related]
12. A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches.
Negahdaripour M; Eslami M; Nezafat N; Hajighahramani N; Ghoshoon MB; Shoolian E; Dehshahri A; Erfani N; Morowvat MH; Ghasemi Y
Infect Genet Evol; 2017 Oct; 54():402-416. PubMed ID: 28780192
[TBL] [Abstract][Full Text] [Related]
13. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
14. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
15. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
17. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
18. Computational Modeling of Immune Response Triggering Immunogenic Peptide Vaccine Against the Human Papillomaviruses to Induce Immunity Against Cervical Cancer.
Ahmad N; Ali SS; Ahmad S; Hussain Z; Qasim M; Suleman M; Ali S; Nizam-Uddin N; Khan A; Wei DQ
Viral Immunol; 2021 Sep; 34(7):457-469. PubMed ID: 33973819
[TBL] [Abstract][Full Text] [Related]
19. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
20. In Silico Analysis of L1/L2 Sequences of Human Papillomaviruses: Implication for Universal Vaccine Design.
Ghorban Hosseini N; Tebianian M; Farhadi A; Hossein Khani A; Rahimi A; Mortazavi M; Hosseini SY; Taghizadeh M; Rezaei M; Mahdavi M
Viral Immunol; 2017 Apr; 30(3):210-223. PubMed ID: 28388355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]